Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.43 |
| ▸ | BCL2 | P10415 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523330 | 1.00 | MCL1 (0.43) | MCL1BCL2KMT2AFGFR1BCL2L1 | |
| SCHEMBL29523407 | 0.83 | MCL1 (0.60) | MCL1BCL2KMT2ABCL2L1 | |
| SCHEMBL14935279 | 0.83 | MCL1 (0.60) | MCL1BCL2KMT2ABCL2L1 | |
| SCHEMBL14935214 | 0.81 | FGFR1 (0.45) | MCL1FGFR1FLT1FGFR3 | |
| SCHEMBL14935393 | 0.77 | MCL1 (0.58) | MCL1BCL2BCL2L1 | |
| SCHEMBL14935459 | 0.77 | MCL1 (0.58) | MCL1BCL2KMT2ABCL2L1GRM2 | |
| SCHEMBL14935365 | 0.74 | MCL1 (0.63) | MCL1BCL2KMT2AFGFR1BCL2L1 | |
| SCHEMBL14935441 | 0.73 | MCL1 (0.69) | MCL1BCL2FGFR1BCL2L1 | |
| SCHEMBL14935244 | 0.73 | CNR2 (0.40) | MCL1BCL2KMT2AFGFR1BCL2L1 | |
| SCHEMBL14935312 | 0.71 | FGFR1 (0.50) | MCL1KMT2AFGFR1FLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614333-B2 | Acenaphtho heterocyclic compound and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-12-24 | — | — | US | claimed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | claimed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| EP-3179991-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| US-8614333-B2 | Acenaphtho heterocyclic compound and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-12-24 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | MCL1 30/4885BCL2 7/4885KMT2A 681/4885 |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | MCL1, BCL2L1, BCL2 | MCL1 1/4885BCL2 3/4885KMT2A 3221/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | MCL1 30/4885BCL2 7/4885KMT2A 681/4885 |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | MCL1 30/4885BCL2 7/4885KMT2A 681/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | MCL1 30/4885BCL2 7/4885KMT2A 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.